<DOC>
	<DOCNO>NCT01139164</DOCNO>
	<brief_summary>This study patient diagnose high-risk hematological malignancy . The main purpose study confirm previously publish result stem cell transplantation reduce intensity pre-transplant conditioning . Patients assign 1 3 regimen depend patient 's diagnosis . Participants follow transplant team remainder patient 's life . Patient 's visit MUSC daily , visit reduce frequent visit 6 month . After 6 month , visit reduce depend patient 's condition .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning Treatment High-risk Hematological Malignancies ( V3 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>A proven diagnosis one condition Table 1 . Prior therapy include blood marrow transplant exclude patient reduce intensity transplant . Age &lt; 75 year . Pediatric patient eligible age 1 month 18 year transplant physician believe comorbid condition significantly increase risk standard transplant regimen . HIV antibody negative . ECOG performance status 03 , ( equivalent Karnofsky Lansky performance score patient &lt; 18yrs , see appendix 2 ) Availability HLAidentical relate donor suitable alternative donor , ( â‰¥7/8 allele match A , B , C DRB ) . Syngeneic transplant allow protocol . Due complexity study , patient prior enrollment assess PI coPI . Patient marrow failure state immune deficiency syndrome undergoing stem cell transplant must review one investigator determine eligibility study . Adequate insurance coverage ( financial resource ) cover cost associate patient 's transplant , case patient eligible cohort C , cover cost associate I 131 Tositumomab treatment . Active CNS involvement malignant disease . Pregnancy . Fertile men woman unwilling use contraceptive technique study period . Creatinine clearance &lt; 30 ml/min . Left ventricular ejection fraction &lt; 30 % clinical cardiac failure uncontrolled medical therapy . Pulmonary disease require supplemental oxygen therapy . Patients estimated life span less 1 year due medical illness condition treat study . Donor Selection : Inclusion Criteria Major HLA identical relative genotypically match unrelated donor ( 78/8 allele ) . Donors must meet selection criterion define Foundation Accreditation Cell Therapy ( FACT ) screen per American Association Blood Banks ( AABB ) guideline . Exclusion Criterion Positive antidonor HLA antibody . Identical twin .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>high-risk hematological malignancy</keyword>
</DOC>